Opportunistic infections after liver transplantation in patients infected with human immunodeficiency virus
Elina Teicher, Jean‐Charles Duclos‐Vallée – 7 December 2011
Split liver transplantation using extended right grafts: The natural history of segment 4 and its impact on early postoperative outcomes
Ailton Sepulveda, Olivier Scatton, Hadrien Tranchart, Hervé Gouya, Fabiano Perdigao, Fabien Stenard, Denis Bernard, Filomena Conti, Yvon Calmus, Olivier Soubrane – 6 December 2011 – Split liver transplantation (SLT) using extended right grafts is associated with complications related to ischemia of hepatic segment 4 (S4), and these complications are associated with poor outcomes. We retrospectively analyzed 36 SLT recipients so that we could assess the association of radiological, biological, and clinical features with S4 ischemia.
Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma
Chakri Panjala, Justin H. Nguyen, Ali N. Al‐Hajjaj, Barry A. Rosser, Raouf E. Nakhleh, Mellena D. Bridges, Stephen J. Ko, Steven J. Buskirk, George P. Kim, Denise M. Harnois – 5 December 2011 – The very early experience with liver transplantation (LT) for cholangiocarcinoma (CC) was dismal because of the poor survival outcomes and the high recurrence rates. However, LT for CC in conjunction with neoadjuvant chemoradiation recently has shown encouraging results, although the data are extremely limited.
Progression of polycystic disease of the liver after transplantation
Basant Mahadevappa, Ganesh Gunasekaran, Sunu John Philip, Caroline Rochon, Patricia Sheiner – 5 December 2011
Meeting report of the 2011 joint international congress of the international liver transplantation society, the European liver and intestine transplant association, and the liver intensive care group of Europe
Josh Levitsky, Olaf Guckelberger – 5 December 2011 – The International Liver Transplantation Society held its yearly meeting as a joint conference with the European Liver and Intestine Transplant Association and the Liver Intensive Care Group of Europe at the Valencia Congress Center (Valencia, Spain) from June 22 to 25, 2011.
Cell therapies for liver diseases
Yue Yu, James E. Fisher, Joseph B. Lillegard, Brian Rodysill, Bruce Amiot, Scott L. Nyberg – 5 December 2011 – Cell therapies, which include bioartificial liver support and hepatocyte transplantation, have emerged as potential treatments for a variety of liver diseases. Acute liver failure, acute‐on‐chronic liver failure, and inherited metabolic liver diseases are examples of liver diseases that have been successfully treated with cell therapies at centers around the world.
Donation after cardiac death liver transplantation: Time for policy to catch up with practice
Anton I. Skaro, Edward Wang, Vadim Lyuksemburg, Michael Abecassis – 5 December 2011
New index for assessing the chronotropic response in patients with end‐stage liver disease who are undergoing dobutamine stress echocardiography
Wojciech Rudzinski, Alfonso H. Waller, Amit Prasad, Sunita Sood, Christine Gerula, Arun Samanta, Baburao Koneru, Marc Klapholz – 5 December 2011 – The inability to achieve 85% of the maximum predicted heart rate (MPHR) on dobutamine stress echocardiography (DSE) is defined as chronotropic incompetence and is a predictor of major cardiac events after orthotopic liver transplantation (OLT). The majority of patients with end‐stage liver disease (ESLD) receive beta‐blockers for the prevention of variceal bleeding.
Recipient‐Donor race mismatch for African American liver transplant patients with chronic hepatitis C
Varun Saxena, Jennifer C. Lai, Jacqueline G. O'Leary, Elizabeth C. Verna, Robert S. Brown, R. Todd Stravitz, James F. Trotter, Kartik Krishnan, Norah A. Terrault, for the Consortium to Study Health Outcomes in HCV Liver Transplant Recipients – 5 December 2011 – African American (AA) recipient‐donor race mismatch has been associated with graft loss and mortality, but studies of an association between race mismatch and hepatitis C virus (HCV) disease severity are lacking.
Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: Comparable survival and recurrence
Lakhbir Sandhu, Charbel Sandroussi, Markus Guba, Markus Selzner, Anand Ghanekar, Mark S. Cattral, Ian D. McGilvray, Gary Levy, Paul D. Greig, Eberhard L. Renner, David R. Grant – 5 December 2011 – Several studies have reported higher rates of recurrent hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT) versus deceased donor liver transplantation (DDLT). It is unclear whether this difference is due to a specific biological effect unique to the LDLT procedure or to other factors such as patient selection.